Location History:
- Ann Arbor, MI (US) (2013)
- Marseille, FR (2015 - 2017)
- Marseilles, FR (2020)
Company Filing History:
Years Active: 2013-2020
Title: The Innovative Contributions of Christophe Ginestier
Introduction
Christophe Ginestier is a prominent inventor based in Marseille, France. He has made significant contributions to the field of cancer research, particularly through his innovative patents. With a total of 4 patents, Ginestier's work focuses on advancing treatment methods for cancer patients.
Latest Patents
Ginestier's latest patents include groundbreaking inventions related to the IL8-CXCR1 pathway. One of his notable patents is centered on anti-CXCR1 compositions and methods. This invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor, such as an anti-CXCR1 antibody or Repertaxin, either alone or in combination with additional chemotherapeutic agents. The goal is to effectively kill both non-tumorigenic and tumorigenic cancer cells in a subject. Additionally, his patents offer compositions and methods for detecting and isolating solid tumor stem cells in patients, based on the presence of CXCR1 or FBXO21.
Career Highlights
Christophe Ginestier is affiliated with the University of Michigan, where he continues to contribute to cancer research and innovation. His work has garnered attention for its potential to improve cancer treatment outcomes and enhance the understanding of tumor biology.
Collaborations
Ginestier collaborates with esteemed colleagues in the field, including Max S Wicha and Gabriela Dontu. These partnerships enhance the research efforts and broaden the impact of their collective work in cancer treatment.
Conclusion
Christophe Ginestier's innovative patents and research contributions are paving the way for new cancer treatment methodologies. His dedication to advancing medical science is evident in his work, which holds promise for improving patient outcomes in the fight against cancer.